Answers are grounded in this paper and cite their sources.
Adoptive T cell receptor (TCR)–based immunotherapy offers a powerful strategy to target solid tumors. However, how the physical properties of the antigen-presenting interface regulate T cell metabolic programming remains poorly defined. Here we develop synthetic viscoelastic activating cells (SynVAC), artificial antigen-presenting cells whose stress-relaxation kinetics are chemically tuned independently of stiffness and of peptide–MHC (pMHC) and co-stimulatory ligand density. SynVAC-pMHC provides a defined, scalable platform that outperforms monocyte-derived dendritic cells to enrich antigen-specific CD8 + T cells. Fast-relaxing SynVAC-pMHC amplifies TCR signaling and mTOR activity, drives metabolic changes, and programs antigen-specific T cells toward an energetically favorable state with improved memory-like features after expansion. TCR-T cells expanded using fast-relaxing SynVAC-pMHC exhibit superior persistence and durable antitumor activity in melanoma and ovarian cancer models. These results establish cell-mimetic viscoelasticity as a key biophysical cue governing T cell metabolism and differentiation and offer a fully synthetic strategy for manufacturing potent TCR-T cells.
No takes yet. Share an insight, caveat, or question.
Yang et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: